title: Molecular heterogeneity of hCGbeta--related glycoproteins and the clinical relevance in trophoblastic and non-trophoblastic tumors.
abstract: We analyzed immunoreactive hCG/hCGbeta (IR-beta) in the sera and urine of patients with trophoblastic diseases and non-trophoblastic tumors by using enzyme immunoassays (EIAs) specific for intact hCG, free hCG beta, and beta-core fragment of hCG (beta-CF). In trophoblastic diseases, while intact hCG and free hCGbeta were contained in both serum and urine, the beta-CF could be detected only in the urine of the patients. The relative contribution of the beta-CF to the total urinary IR-beta accounted for about 30-50% in normal early pregnancy and hydatidiform mole, and more than 60% in choriocarcinoma. We conclude that intact hCG should be measured in the serum rather than in the urine as a tumor marker for trophoblastic diseases, and suggested that the ratios of intact hCG, free hCGbeta, and beta-CF to each other may be useful indices in the differential diagnosis of trophoblastic diseases. Ectopic IR-beta was also investigated in the sera and urine of the patients with cervical, endometrial, ovarian, lung, and bladder carcinomas. We found that even when IR-beta could not be detected in the serum, the urine of the same patients with cancer often contained the significant amounts of IR-beta. The chromatographic study indicated that these urinary IR-beta were essentially attributed to beta-CF, leading to the evaluation of urinary beta-CF as a tumor marker. The positive rated of urinary beta-CF were 48% for cervical, 38% for endometrial, and 84% for ovarian, 40% for lung, and 42% for bladder carcinomas. We conclude that ectopic production of hCG beta by non-trophoblastic tumors is not a rare phenomenon and it can be recognized as a tumor marker when beta -CF is measured in urine of the patients.
authors.affiliation: Hyogo Institute of Clinical Research, Akashi, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Nishimura
authors.forename: T
authors.initials: T
authors.lastname: Koizumi
authors.forename: T
authors.initials: T
authors.lastname: Yokotani
authors.forename: R
authors.initials: R
authors.lastname: Taniguchi
authors.forename: K
authors.initials: K
authors.lastname: Morisue
authors.forename: M
authors.initials: M
authors.lastname: Yoshimura
authors.forename: D
authors.initials: D
authors.lastname: Hiranmoy
authors.forename: S
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: H
authors.initials: H
authors.lastname: Yasui
mesh_terms: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism* / Q000652:urine; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000032:analysis* / Q000097:blood / Q000652:urine; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006023:Glycoproteins / Q000032:analysis* / Q000097:blood / Q000652:urine; D006801:Humans; D007124:Immunoenzyme Techniques; D011247:Pregnancy; D014328:Trophoblastic Neoplasms / Q000097:blood / Q000378:metabolism* / Q000652:urine; D014594:Uterine Neoplasms / Q000097:blood / Q000378:metabolism* / Q000652:urine
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018997:Chorionic Gonadotropin, beta Subunit, Human; D006023:Glycoproteins